Piper Sandler Reiterates Overweight Rating on Tempest Therapeutics (TPST) Ahead of Data at ASCO
Tweet Send to a Friend
Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $23.00 price target on Tempest Therapeutics (NASDAQ: TPST) ahead of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
